Skip to Content

Franklin Biotechnology Discovery A FBDIX

Analyst rating as of
NAV / 1-Day Return
162.93  /  1.88 %
Total Assets
1.6 Bil
Adj. Expense Ratio
1.030%
Expense Ratio
1.030%
Fee Level
Low
Longest Manager Tenure
23.48 years
Category
Health
Investment Style
Mid Growth
Min. Initial Investment
1,000
Status
Open
TTM Yield
0.00%
Turnover
33%
Premium

Morningstar’s Analysis

Will FBDIX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A solid but ultimately undifferentiated offering.

Summary

| |

A capable trio leads Franklin Biotechnology Discovery, but limited resources constrain the extent to which the managers can apply their process, limiting the fund to a Morningstar Analyst Rating of Neutral.

Unlock our full analysis with Morningstar Premium